Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma. - Wikidata - awgldk - TriplyDB

Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma.

Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma.

http://www.wikidata.org/entity/Q37481890

about

Glycogen synthase kinase-3β is a pivotal mediator of cancer invasion and resistance to therapy Signal integration and gene induction by a functionally distinct STAT3 phosphoform.Clinicopathological and biological significance of aberrant activation of glycogen synthase kinase-3 in ovarian cancer Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models.STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma.Glycogen synthase kinase-3β is associated with the prognosis of hepatocellular carcinoma and may mediate the influence of type 2 diabetes mellitus on hepatocellular carcinoma.The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia.Glycogen Synthase Kinase 3β Inhibitor (2'Z,3'E)-6-Bromo-indirubin- 3'-Oxime Enhances Drug Resistance to 5-Fluorouracil Chemotherapy in Colon Cancer Cells.Glycogen synthase kinase 3 protein kinase activity is frequently elevated in human non-small cell lung carcinoma and supports tumour cell proliferation.CG0009, a novel glycogen synthase kinase 3 inhibitor, induces cell death through cyclin D1 depletion in breast cancer cells.GSK3β overexpression indicates poor prognosis and its inhibition reduces cell proliferation and survival of non-small cell lung cancer cells Opposing functions of Akt isoforms in lung tumor initiation and progression Glycogen synthase kinase-3β promotes cyst expansion in polycystic kidney disease Transmembrane-Bound IL-15-Promoted Epithelial-Mesenchymal Transition in Renal Cancer Cells Requires the Src-Dependent Akt/GSK-3β/β-Catenin Pathway.Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTPε and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma.Inhibition of glycogen synthase kinase-3 beta induces apoptosis and mitotic catastrophe by disrupting centrosome regulation in cancer cells.GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.GSK-3 promotes cell survival, growth, and PAX3 levels in human melanoma cells Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer.Glycogen synthase kinase-3: a potential preventive target for prostate cancer management Glycogen synthase kinase 3β and cyclin D1 expression in cervical carcinogenesis.A cAMP and CREB-mediated feed-forward mechanism regulates GSK3β in polycystic kidney disease.Inhibition of GSK-3 induces differentiation and impaired glucose metabolism in renal cancer.Glycogen synthase kinase 3 beta: can it be a target for oral cancer.Glycogen Synthase Kinase 3β in Pancreatic Cancer and its Implications in Chemotherapy and Radiation Therapy.Mutant K-Ras increases GSK-3β gene expression via an ETS-p300 transcriptional complex in pancreatic cancer.Glycogen synthase kinase 3 in Wnt signaling pathway and cancer.The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.The emerging role of GSK-3β in the pathobiology of classical Hodgkin lymphoma.GSK-3 inhibition overcomes chemoresistance in human breast cancer.Effects of the GSK-3β inhibitor (2Z,3E)-6-bromoindirubin-3'-oxime upon ovarian cancer cells.Does Wnt/β-catenin pathway contribute to the stability of DNMT1 expression in urological cancer cell lines?Transcriptional regulation, stabilization, and subcellular redistribution of multidrug resistance-associated protein 1 (MRP1) by glycogen synthase kinase 3αβ: novel insights on modes of cadmium-induced cell death stimulated by MRP1.Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer.PANC-1 cells proliferative response to ionizing radiation is related to GSK-3β phosphorylation.Distinct expression and activity of GSK-3α and GSK-3β in prostate cancer.Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.GSK-3β inhibition promotes cell death, apoptosis, and in vivo tumor growth delay in neuroblastoma Neuro-2A cell line.New methods to control neuroblastoma growth.GSK3β mediates pancreatic cancer cell invasion in vitro via the CXCR4/MMP-2 Pathway.

P2860

Q26739711-A6C8D941-1725-4B79-839C-0711D9F8FAC6 Q33602531-752D5713-3846-45DD-AEFD-A92D79314FBC Q33831250-F61C58AA-6326-4205-9618-5AEF250605AC Q33869702-91D5B232-BDA6-4EBE-AC16-B6CD4787BA6A Q33903747-A237C67D-BD8D-4C41-ABEE-9747C810B5A7 Q34089689-32604F6F-7862-4007-BF69-8C4FA4B3F82B Q34156754-944A6737-3938-4D49-8D83-90E99F2C0BEF Q34566456-B84F542E-D1EE-409D-BD43-F064F4660AF7 Q34654039-A474EEFC-9758-4FED-91CA-CF951970B156 Q34658396-D6C6DAB0-4411-47FF-9493-40BF840BED8C Q35117724-0C8DDD20-4F36-466E-BE60-C52699931651 Q35145125-EE067738-8D86-4208-897E-699B546C02CB Q35667570-F58723C2-008F-4B6F-8819-CD63A2A74A2F Q35745099-FE7F8A8D-E288-4596-8E8B-B624A9EDD279 Q35934532-1EDE5F01-6480-40D0-A529-4CA69C505B05 Q35979303-3E87E788-A1C4-42BC-892E-67CD067EFE20 Q36069860-0F0094B5-BF00-4C85-B097-DB4752C131F3 Q36173889-2713420B-C482-4206-BA19-30ECE682CC31 Q36450022-1DFFC5B9-1A1F-4D26-9ACF-7461A31FC80C Q36580561-6DB2C0F1-F406-47A0-B6BB-EC7F41078DDA Q37430271-A6AD0D44-2532-43F4-8C06-7C80541C35F3 Q37529873-C1F8E15B-53CC-4FBE-9687-EA09A0D54E61 Q37640802-E93C23F8-00A5-4B21-A91E-A8736158E987 Q37764097-DB9A6ECC-741E-4FF0-A9AC-3CC0A902F604 Q38221504-4A886AD5-B440-4424-992D-01B36A332194 Q38262388-06B1E08B-901E-47B8-8C03-02F2BD9086F0 Q38645490-4E3DCA12-CC1B-42E7-9AE5-EA778B547A77 Q38695102-34FF5F9F-5AF1-43F6-986A-A540F6F1CE70 Q38756542-F4132D45-F5E0-47F8-A533-97151F072D67 Q38757733-05400E7A-9153-4A39-964D-8207FE2A727A Q38822772-E60E6BBF-B011-484A-9BAB-62FB4CF4EDCD Q38944664-30505076-87F0-40FB-8838-E1EE6982DCF4 Q38951596-BD942272-66A6-4FBE-A813-2DAEE5EF16F5 Q39067484-94778C7A-1A39-4DB5-A2DF-121F0DCA87DC Q39235959-E2F7CDFF-0CCD-4448-8D69-99680C5D9265 Q39357705-48E6B0E0-7D7E-4AC4-9931-E886A08A06A8 Q39463711-68B97A62-83E3-4796-B9FD-8D4A4537A864 Q39619563-CDD14A9C-7713-45D8-BD4F-154F641679F2 Q39741776-8ECA5E73-52BC-437C-B115-CC612632E6FB Q42383020-936A465C-D823-4576-8528-9FC6013AD95E

P2860

Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma.

http://www.wikidata.org/entity/Q37481890

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma.

@en

Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma.

@nl

type

label

Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma.

@en

Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma.

@nl

prefLabel

Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma.

@en

Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma.

@nl

P1433

Q37481890-2213D40D-6A79-47AB-82E5-004CC5DFC936

P1476

Q37481890-65682414-1763-4F20-B65F-024AEFA80BB3

P2093

Q37481890-405A1837-5BBE-4591-8B2A-D780F96319B6

Q37481890-4B51EB3A-B453-429E-AC10-B61BD0247A2D

Q37481890-5DCB401B-95EF-4635-9FA2-7C118CD6AF48

Q37481890-7FC28EC0-F4FF-447F-A1B4-D1F2656A7307

Q37481890-81E84B75-DD76-43C9-B28F-5C12CD9EBDC3

Q37481890-91125870-59C8-4D94-B788-801E87BE1991

Q37481890-A6772E05-A8EC-48B5-9300-74813392E53C

Q37481890-C3931553-EA2C-42FC-AAB5-F77C46B32F74

Q37481890-DCDE5FB4-641E-4BE4-AC21-90A3BD851B90

Q37481890-DDFCD560-A8ED-481F-87BB-281873AFFCF9

P2860

Q37481890-027D60C7-DF70-4687-93E1-D7CA1CB0CD12

Q37481890-067A1D45-5D46-4032-A7A7-30554A38E9D6

Q37481890-09660752-45E2-42AD-A723-854E61660105

Q37481890-09C28A0D-73A6-4BC3-B6FE-DA7494C22DF1

Q37481890-0A563D17-8CF5-48CF-AF55-69FE95D12F95

Q37481890-0BD4CB68-42BD-4280-AF71-1210EE1ECFEB

Q37481890-12F2639E-11A6-431A-A423-AF340E2CC24B

Q37481890-1B029417-658D-4E6D-804B-A072D7D61D5C

Q37481890-258BB85F-B058-425A-B4B4-62B14D69F02F

Q37481890-269CA5B9-964C-4D55-BFD3-5A3259BFC53C

P2888

Q37481890-A869EA5D-13DE-417E-A413-95B27CA7DA95

P304

Q37481890-FB9E206D-4240-4104-90E0-E2A828635FFF

P31

Q37481890-207BB007-93F2-4181-ACE8-FF9C29A02507

P356

Q37481890-D5A9F45E-722B-4087-A4FE-FB053E5C8605

P407

Q37481890-FA67C99B-0872-4A38-B774-3A1F87462F7E

P433

Q37481890-067A86DF-55C7-4333-BF85-1788AD199605

P478

Q37481890-EC4BA7E7-7B82-4495-B8DE-E611DE914DDC

P577

Q37481890-3E0E26FF-3225-4081-B651-9670E07B87CA

P5875

Q37481890-F5EF2E2D-F24C-4EC1-A06A-517BBF494225

P6179

Q37481890-5CF1CFE4-7F0C-4872-BC0D-7A3E1B42027F

P698

Q37481890-924129D0-C5B8-4586-AF22-0F9D7171AA17

P932

Q37481890-3BA2EC17-C7FD-4403-B435-317A559F3CF3

P356

P1433

British Journal of Cancer

P1476

Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma.

@en

P2093

A Muto

http://www.w3.org/2001/XMLSchema#string

A Ougolkov

http://www.w3.org/2001/XMLSchema#string

D Billadeau

http://www.w3.org/2001/XMLSchema#string

H Kawazoe

http://www.w3.org/2001/XMLSchema#string

K Yuuki

http://www.w3.org/2001/XMLSchema#string

M Oya

http://www.w3.org/2001/XMLSchema#string

S Naito

http://www.w3.org/2001/XMLSchema#string

T Motoyama

http://www.w3.org/2001/XMLSchema#string

V Bilim

http://www.w3.org/2001/XMLSchema#string

Y Tomita

http://www.w3.org/2001/XMLSchema#string

P2860

Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation

Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418

Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation

The glamour and gloom of glycogen synthase kinase-3

Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription.

Chemotherapy for renal cell carcinoma.

Cytokine therapy for metastatic renal cell carcinoma.

Renal-cell carcinoma.

Targeted therapy for metastatic renal cell carcinoma.

Renal cell carcinoma guideline.

P2888

P304

2005-2014

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605437

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38096584

http://www.w3.org/2001/XMLSchema#string

P6179

1016108440

http://www.w3.org/2001/XMLSchema#string

P698

19920820

http://www.w3.org/2001/XMLSchema#string

P932

2795437

http://www.w3.org/2001/XMLSchema#string